TCRT
Alaunos Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.20
−25.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.26
From 52W high−72.48%
Volume32.36M
Market cap$3.05M
P/E (TTM)—
P/S (TTM)1016.2x
Div yield—
Key dataSep 18, 2026
Open
$2.26
From 52W high
−72.48%
Volume
32.36M
Market cap
$3.05M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
28.8
MomentumView details →
1D Return
−25.00%
YTD Return
−66.25%
SummaryUpdated Jun 1, 2026
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) is a clinical-stage biotechnology company focused on developing innovative cancer treatments through engineered cell therapies. Originally founded as ZIOPHARM Oncology in 2003 and renamed Alaunos Therapeutics in January 2022, the Houston-based company has evolved from a traditional oncology drug developer into a specialized cell therapy company. The company went public in 2005 and has since pivoted to focus exclusively on adoptive T-cell receptor (TCR) engineered T-cell therapies for treating solid tumors, representing a cutting-edge approach in cancer immunotherapy.
Similar companies
Latest newsMore news →